AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY OF PF-07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATOR CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK4/6 INHIBITOR-BASED THERAPY

16448C4551002-NCT07062965OpenAN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY OF PF-07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATOR CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK4/6 INHIBITOR-BASED THERAPYC4551002NCT07062965IndustrialAdultTreatmentIIIOtherChitalia, Ami; Chitalia, Ami; Kurian, ShwetaMedStar Health and GUMC; Medstar Franklin Square Medical Center : Amy Avergas; Medstar Good Samaritan Hospital; Medstar Washington Hospital CenterBreastOncology GroupMHRI Oncology Baltimore; MHRI Washington Cancer Institute6959Amy AvergasAmy AvergasAmy.m.avergas@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>